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Abstract
Carbonic anhydrase IX (CAIX) is a transmembrane enzyme found to be overexpressed in various tumors and associated with tumor
hypoxia. Ligands binding this target may be used to visualize hypoxia, tumor manifestation or treat tumors by endoradiotherapy.
Methods: Phage display was performed with a 12 amino acid phage display library by panning against a recombinant
extracellular domain of human carbonic anhydrase IX. The identified peptide CaIX-P1 was chemically synthesized and tested
in vitro on various cell lines and in vivo in Balb/c nu/nu mice carrying subcutaneously transplanted tumors. Binding, kinetic
and competition studies were performed on the CAIX positive human renal cell carcinoma cell line SKRC 52, the CAIX
negative human renal cell carcinoma cell line CaKi 2, the human colorectal carcinoma cell line HCT 116 and on human
umbilical vein endothelial cells (HUVEC). Organ distribution studies were carried out in mice, carrying SKRC 52 tumors. RNA
expression of CAIX in HCT 116 and HUVEC cells was investigated by quantitative real time PCR.
Results: In vitro binding experiments of
125I-labeled-CaIX-P1 revealed an increased uptake of the radioligand in the CAIX
positive renal cell carcinoma cell line SKRC 52. Binding of the radioligand in the colorectal carcinoma cell line HCT 116 increased
with increasing cell density and correlated with the mRNA expression of CAIX. Radioligand uptake was inhibited up to 90% by
the unlabeled CaIX-P1 peptide, but not by the negative control peptide octreotide at the same concentration. No binding was
demonstrated in CAIX negative CaKi 2 and HUVEC cells. Organ distribution studies revealed a higher accumulation in SKRC 52
tumors than in heart, spleen, liver, muscle, intestinum and brain, but a lower uptake compared to blood and kidney.
Conclusions: These data indicate that CaIX-P1 is a promising candidate for the development of new ligands targeting
human carbonic anhydrase IX.
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Introduction
The outcome of cancer treatment can be influenced by the
microenvironment within a solid tumor. One of the factors that
influence tumor progression is hypoxia. Tumor hypoxia is
associated with a less favourable phenotype, characterized by
high invasiveness, increased potential for metastasis and poor
prognosis, resulting in reduced overall survival [1,2]. Subphysio-
logic levels of oxygen in the tumor lead to an up to 3-fold increase
of resistance against antineoplastic therapy [3]. Furthermore,
tumor hypoxia influences the migration activity of endothelial
cells, resulting in an amplified signalling for angiogenesis [4].
Low oxygen tension results in the activation of a series of
transcriptional regulators including hypoxia inducible factor 1
(HIF-1) [5]. HIF-1 has a central role as oxygen threshold in
mammalian cells. Under hypoxic conditions, HIF-1 binds to
hypoxia response elements (HRE) of its target genes and induces
their expression [6]. One of the inducible targets of HIF-1
transcriptional activity is carbonic anhydrase IX (CAIX) [7].
CAIX is a member of a family of zinc metalloenzymes, which
catalyse the hydration of carbon dioxide into carbonic acid. It is a
membrane associated glycoprotein, consisting of an extracellular
catalytic domain extended with a proteoglycan-like region, a
transmembrane anchor and a short C-terminal cytoplasmic tail
[8]. The protein is found to be overexpressed in various human
tumors, such as carcinomas of the colon, kidney and lung
[9,10,11], and various clinical studies have demonstrated a
correlation between CAIX expression and disease prognosis
[12,13].
The leading role of tumor hypoxia in increased therapy
resistance reveals the necessity for the development of hypoxia
imaging assays. Such assays would allow a better characterization
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important for targeted therapies, and the development of strategies
for predicting treatment outcome. In this respect, radiolabeled
nitroimidazole compounds find wide clinical application [14].
These compounds are reduced by intracellular reductases into
reactive metabolites, which subsequently bind to thiol groups of
intracellular proteins, resulting in accumulation within hypoxic
cells [15].
Still, there is increasing interest in the development of molecular
imaging strategies based on ligands that bind selectively to target
proteins overexpressed at hypoxic sites. The fact that CAIX
represents an endogenous marker for cellular hypoxia with
predictive potential and that it is easily accessible through its
extracellular domain make carbonic anhydrase IX to an attractive
molecule for targeting approaches. A further interesting feature is
its strong overexpression in renal cell carcinoma. Monoclonal
antibodies with high affinity to human carbonic anhydrase IX
have already been generated and tested for diagnosis as well as for
treatment [16,17,18].
Peptides are an attractive alternative to antibodies. They possess
favourable pharmacokinetic properties through their small size,
such as rapid clearance from blood, while lacking the immuno-
genic potential of antibodies. Furthermore, peptides are easy and
cheap to synthesize. Therefore, there is increasing interest in the
development of new peptide ligands with specific targeting
abilities.
A very promising tool for the identification of new specific
binders is the phage display technology. The method has found
wide application for the identification of new receptors and natural
ligands, mapping and mimicking epitopes or isolating specific
antigens that bind to bioactive compounds [19]. Phage display was
also successfully applied for the selection of novel peptides that
target organs, tumors or cell types [20,21].
In this study we applied the phage display technology for the
identification of a new peptide ligand binding specifically to
human carbonic anhydrase IX. Panning was performed using the
recombinant extracellular domain of CAIX as target structure.
The identified peptide CaIX-P1 was synthesized and its binding
properties were evaluated in vitro on various cell lines. Further-
more, in vivo organ distribution studies in tumor bearing mice were




All cell lines were cultivated at 37uC in a 5% CO2 incubator.
The human renal cell carcinoma cell line SKRC 52 was obtained
by O. Boerman (Univ. of Nijmegen, The Netherlands). SKRC 52
and CaKi 2 cells, as well as the human colorectal carcinoma cell
line HCT 116 were cultured in RPMI 1640 with GlutaMAX
(Invitrogen) containing 10% (v/v) fetal calf serum (Invitrogen).
Primary isolated human umbilical vein endothelial cells (HUVEC:
Promocell, Heidelberg, Germany) were cultured in serum reduced
(5% fetal calf serum [FCS]) modified Promocell medium (MPM),
supplemented with 2 ng/mL VEGF and 4 ng/mL basic fibroblast
growth factor (bFGF).
Recombinant isolation of the extracellular domain of
carbonic anhydrase IX
For recombinant isolation of the extracellular domain of human
carbonic anhydrase IX (CAIX) the Flp-In system (Invitrogen life
technologies) was used. The gene encoding for human carbonic
anhydrase IX inserted into a pCMV6-XL5 vector was obtained
from Origene, Rockville. The primers for PCR amplification of
the sequence encoding for the extracellular domain of CAIX were
forward: 59-AAC TTA AGC TTG GGG CCG CCA CCA TGG
CTC CCC TGT GCC CCA-39 and reverse: 59-GGC TCC GGA
TCC ATG TCC CTG CCC TCG ATG TCA CCA GCA GCC
AGG CAG-39. After PCR amplification, the sequence encoding
for the extracellular domain of CAIX was inserted into the
HindIII and BspEI sites of pSEC-EGP-2-Fcc vector (Affimed,
Heidelberg). The fragment CAIX-Fc was cut by HindIII and
XhoI and inserted into pcDNAEpcam vector (Affimed, Heidel-
berg). This vector was cotransfected with the Flp recombinase
expression vector pOG44 into the Flp-In
TM-293 human embry-
onic kidney host cell line, as described in the Flp-In protocol.
Thereafter, a selection for hygromycin resistant cells was
performed. The expressed protein was isolated and purified from
the incubation medium through a HiTrap
TMMabSelect SuRe
TM
column. Qualitative control was performed by ELISA and western
blot analysis (data not shown).
Selection of peptides binding carbonic anhydrase IX
A linear 12-amino acid peptide library (Ph.D.12; New England
Biolabs) was used for biopanning. Panning was performed on
immobilized recombinant extracellular domain of human carbon-
ic anhydrase IX. Immobilized recombinant extracellular domain
of the epidermal growth factor receptor (EGFR) was used for
negative selection. For immobilization protein was incubated in
Maxisorp plates (50 nM) for 24 h at 4uC. Each selection round
was conducted as follows: 10
11 plaque-forming units were added
on immobilized negative target (EGFR) in 96well plates. After 1 h
incubation at room temperature medium was transferred in 96-
wells containing the immobilized positive target (CAIX). Incuba-
tion was carried out for 1 h at room temperature. Subsequently,
medium was removed and the target was washed 10 times with
100 ml Tris Buffered Saline with Tween (TBST) pH 7.4. Elution
of the bound phages was performed through incubation for
10 min with 10 ml 0.2 M glycine/HCl buffer pH 2.2, containing
1 mg/mL bovine serum albumin (BSA) at room temperature.
After neutralization with 15 ml Tris/HCl buffer pH 9.1, centrifu-
gation was performed for 5 min at 1000 rpm. Supernatant was
collected and 10 ml were used for phage titration on isopropyl b-D-
1-thiogalactopyranoside/X-Gal (IPTG/X-Gal) (Fermentas) lysog-
eny broth agar plates. The remaining supernatant was used for
amplification in 20 mL of ER2537 bacteria according to the
manufacturer’s protocol. After 7 selection rounds, clones were
picked and phage single-stranded isolation was performed
(QIAprep Spin M13 Kit; Qiagen). DNA sequencing was carried
out and the displayed peptide was identified through analysis with
the HUSAR map (HUSAR Biocomputing Service at the German
Cancer Research Center, Heidelberg, Germany).
Peptides
The peptide CaIX-P1 (YNTNHVPLSPKY) and its derivative
CaIX-P1-2-12 (NTNHVPLSPKY) were obtained by solid phase
peptide synthesis using Fmoc coupling protocols. CaIX-P1 and
CaIX-P1-2-12 were synthesized on an ABI 433 A peptide
synthesis reactor (Applied Biosystems). The peptides were purified
by high performance liquid chromatography (HPLC) on a
Chromolith Semi Prep Column RPe18, 106100 mm (Merck,
Darmstadt, Germany), with a linear gradient of water and
acetonitrile containing 0.1% trifluoroacetic acid and subsequent
lyophilization. The mass of the products was determined by mass
spectrometry analysis on a matrix-assisted laser desorption
ionization time-of-flight mass spectrometer (MALDI-3; Kratos
instruments). Labeling with
125I and
131I was performed using the
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and analyzed on a Chromolith Performance RP-18e 10064.6 mm
column (Merck) using a linear gradient of water and acetonitrile
containing 0.1% trifluoroacetic acetic acid. The iodination
product of CaIX-P1 was a mixture of iodinated species that could
not be separated from each other due to their similar retention
times in the HPLC chromatograms. All experiments were
conducted under the same radiolabeling conditions.
Binding experiments on immobilized protein
Binding of
125I-labeled CaIX-P1 was performed on immobilized
recombinant extracellular domain of human CAIX and of EGFR.
For immobilization the target proteins CAIX and EGFR were
incubated at a concentration of 50 nM in 24-well plates for 24 h.
Thereafter, the plates were washed three times with 500 mlP B S
pH 7.4. Incubation with
125I-CaIX-P1 was performed in 500 ml
PBS pH 7.4 for 30 min. After incubation the plates were washed
three times with 500 ml ice cold PBS pH 7.4. The target proteins
were degraded with 500 ml NaOH 0.3 mol/L and the radioactivity
wascounted with a c-counter.Bound radioactivitywascalculated as
percentage applied dose. In order to evaluate the specificity of the
radioligand binding, competition experiments with the unlabeled
CaIX-P1 peptide at a concentration of 10
24 M were carried out.
In vitro binding experiments
For binding experiments 3610
5 CAIX positive SKRC 52 cells
were seeded into 6-well plates and cultivated in 3 mL of incubation
medium at 37uC for 24 h. After cell blocking with RPMI 1640
(without FCS) containing 1% BSA, the medium was replaced with
1 mL of fresh medium (without FCS) containing 0.5–1.5610
6 cpm
of
125I-labeled peptide and incubation was performed for time
periods varying from 10 min to 6 h at 37uC. To determine specific
versus nonspecific binding, the cells were incubated with the
unlabeled CaIX-P1 peptide at concentrations varying from 10
24 to
10
210 mol/L. Octreotide was used as negative control competitor.
After incubation the medium was removed and the cells were
washed three times with 1 mL ice cold PBS in order to remove the
unbound radiolabeled peptide. Subsequently, the cells were lysed
with 0.5 mL NaOH 0.3 mol/L and the radioactivity was measured
with a c-counter. Bound radioactivity was calculated as percentage
applied dose per 10
6 cells. Binding experiments were also
performed on HCT 116 cells and on human umbilical vein
endothelial cells (HUVEC) at various cell densities. CAIX negative
CaKi-2 cells were used as negative control.
Binding kinetic of the
125I-labeled CaIX-P1-2-12 was performed
on SKRC 52 cells for incubation periods varying from 10 min to
2 h at 37uC.
Internalization studies
Subconfluent cell cultures of SKRC 52 cells were incubated
with
125I-CaIX-P1 for 10 min, 60 min, 120 min and 240 min at
37uC and 4uC. Cellular uptake was stopped by removing the
medium and washing three times with 1 mL PBS. Subsequently,
cells were incubated with 1 mL of glycine-HCl 50 mmol/L in PBS
(pH 2.8) for 10 min at room temperature, in order to remove the
surface bound activity. The cells were then washed with 3 mL of
ice-cold PBS and lysed with 0.5 mL of NaOH 0.3 mol/L. The
surface and the internalized radioactivity were measured with a c-
counter and calculated as % applied dose per 10
6 cells.
Stability studies
The stability of CaIX-P1 was investigated in human serum. The
peptide was incubated at 37uC in human serum at a concentration
of 10
24 mol/L. At time points varying from 5 min to 2 h aliquots
were taken, mixed with equal volume acetonitrile to precipitate
serum proteins and centrifuged for 5 min at 13,000 rpm. The
supernatant was analyzed with HPLC on a Chromolith Perfor-
mance RP-18e 10064.6 mm column (Merck) using a linear
gradient of water and acetonitrile containing 0.1% trifluoroacetic
acid. Samples of CaIX-P1 and its fragments in human serum were
isolated and analyzed by MALDI-TOF mass spectrometry.
In vivo experiments
Organ distribution studies were performed in 9-week-old female
Balb/c nu/nu mice, carrying subcutaneously transplanted SKRC
52 tumors. Animals were obtained from Charles River WIGA and
housed in VentiRacks (BioZone Global). A cell suspension of
4610
6 cells in OPTI-MEM (Gibco, Invitrogen Life Technologies)
was injected subcutaneously into the mouse flank and the tumors
were grown to a size of 1.0 cm
3.
131I-labeled CaIX-P1 was
injected into the tail vein of the animals (approximately 1 MBq)
and at 15 min, 60 min and 240 min after injection the animals
were sacrificed. Tumor, blood and selected tissues (heart, spleen,
liver, kidney, muscle, intestinum and brain) were removed,
drained of blood, weighed and the radioactivity was measured in
a c-counter (LB 951G; Berthold Technologies) Also 3 aliquots of
the tracer solution used for injection were measured. The organ
uptake was calculated as percentage injected dose per gram tissue
(% ID/g). In order to investigate the in vivo specificity, blocking
experiments were performed. For in vivo blocking, the radioligand
was co-injected with 100 mL unlabeled CaIX-P1 peptide at a
concentration of 10
23 M and organ distribution was carried out
15 min and 60 min after intravenous application.
For determination of the chemical form of the circulating
radioactivity in the blood of the animals, samples of blood were
taken at 1 h post injection, centrifuged and serum analysis was
performed by HPLC.
All animal experiments were carried out in conformity with the
German law for protection of animals and are in compliance with
European laws. Study approval was received by the Regierung-
spra ¨sidium Karlsruhe, Abteilung 3, Baden-Wu ¨rttemberg, Ger-
many, File reference: 35-9185.81/G-132/04.
Real time quantitative PCR
Total cellular RNA was isolated from confluent HCT 116 and
HUVEC cells in 10 cm cell culture dishes using the Trizol method
(TRIzol Reagent, Invitrogen). Cellular RNA was also isolated
from HCT 116 cells in 6-wells at various cell densities. RNA
extraction was carried out with a standard phenol-chloroform
protocol. RNA concentration was measured with a NanoDrop
spectrophotometer (ND-1000 PeqLab Biotechnologie GmbH,
Germany). 500 ng was transcribed into DNA using M-MLV
reverse transcriptase, 50 pmol random hexamer and 100 pmol of
oligo(dT) primers (Promega, Madison, WI, USA). The Light-
Cycler FastStart DNA Master Hybridization Probes kit was used
for quantification of relative mRNA transcript levels on a Light
Cycler (Roche Applied Sciences), applying the TaqMan method-
ology. Normalization was performed using b2-microglobulin as
house keeping gene. Primers were obtained from Applied
Biosystems (Foster City, CA, USA).
Statistics
Statistical comparisons between groups were performed by the
Student’s t test using the SIGMASTAT program (Jandel
Scientific, Erkrath, Germany). A p value of 0.05 or less was
considered statistically significant.
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Selection of peptides binding the extracellular domain of
carbonic anhydrase IX
In order to identify human carbonic anhydrase IX specific
binding peptides, phages expressing 12mer peptides on their
surface were applied to ex vivo selection rounds on immobilized
recombinant extracellular domain of CAIX. Recombinant
extracellular domain of the epidermal growth factor receptor
(EGFR) was used for negative control selection. After 7 selection
rounds, single-stranded DNA from isolated bound phages was
sequenced. All 20 clones sequenced, displayed the same peptide
sequence: YNTNHVPLSPKY (CaIX-P1).
Binding experiments on immobilized protein
Binding of CaIX-P1 was investigated on immobilized recom-
binant target protein. As negative control immobilized recombi-
nant EGFR protein was used. Binding of the radioligand was 8.5%
on the extracellular domain of CAIX. Co-incubation of the
radioligand with the unlabeled CaIX-P1 peptide at a concentra-
tion of 10
24 M led to a binding inhibition of 93% (p,0.05).
Experiments on the negative control target (EGFR) revealed a
reduced binding to the background level (p,0.05) (Figure 1).
In vitro binding and competition experiments
In vitro binding of CaIX-P1 was investigated on various cell lines.
Cells were incubated with the radioligand in serum free medium in
order to avoid peptide degradation. The in vitro binding
experiments demonstrated the highest uptake for the CAIX
positive renal cell carcinoma cell line SKRC 52. In particular, the
binding capacity in SKRC 52 cells was about 2.5% applied dose
per 10
6 cells after 60 min incubation with the radioligand. Binding
of
125I-CaIX-P1 in the colorectal carcinoma cell line HCT 116
was 1.0 to 1.5%. Performing binding experiments in the CAIX
negative human renal cell carcinoma cell line CaKi 2 and in
human umbilical vein endothelial cells (HUVEC), the binding
capacity was found to be reduced to the background level with
0.4% of the applied dose per 10
6 cells on CaKi 2 and HUVEC
cells (Figure 2A). The difference in the binding capacity between
the positive tumor cell lines SKRC 52 and HCT 116 and the
negative control cell lines CaKi 2 and HUVEC was found to be
highly significant with p,0.01.
Co-incubation of
125I-labeled CaIX-P1 with the unlabeled
peptide in SKRC 52 cells resulted in a concentration dependent
inhibition of the radioligand binding with a maximal inhibition of
90% at 10
-4 mol/L (p,0.01) and an IC50 value of 1.7560.49 mM
(Figure 2B). Using octreotide as negative control competitor at the
same concentration the uptake of
125I-CaIX-P1 on SKRC 52 cells
was not influenced (Figure 2C).
Kinetic studies
Kinetic studies of
125I-CaIX-P1 in SKRC 52 cells, with
incubation periods varying from 10 min to 6 h, revealed a time
dependent decrease of the radioligand uptake. Particularly,
maximal uptake of 3.8% was reached after an incubation period
of 10 min. Thereafter a time-dependent decrease was noticed with
the bound activity reaching a value of about 1.6% after 6 h of
incubation (Figure 2D).
Internalization studies
To distinguish between surface bound and internalized peptide,
in vitro internalization was investigated in SKRC 52 cells. For those
studies the surface bound peptide was removed by including an
acidic wash step in the washing procedure. After 10 min
incubation with
125I-CaIX-P1 at 37uC, the internalized radioac-
tivity was measured as about 45% of the total bound activity, while
after 60 min incubation about 60% of the total uptake was found
to be internalized into the SKRC 52 cells. For longer incubation
periods of 120 and 240 min internalized activity was reduced to
about 30% of the total uptake. Internalization experiments were
also performed at 4uC demonstrating a reduction of both total and
internalized radioactivity (p,0.05). The measured internalized
activity at 4uC was reduced to the background level of ,0.3%
applied dose per 10
6 cells (Figure 3).
Quantitative real time PCR and
125I-CaIX-P1 binding in
HCT 116 and HUVEC cells
Quantitative real time PCR analysis showed an upregulation of
CAIX mRNA in the human colorectal carcinoma cell line HCT
116 with increasing cell density (Figure 4A). The mRNA content
correlated with the CaIX-P1 uptake in HCT 116 cells. In
particular, radioligand binding was found to increase with
increasing cell number in the 6-well plate (p,0.05) (Figure 4B).
qRT-PCR analysis demonstrated higher CAIX mRNA levels
for HCT 116 cells compared to HUVEC cells at same density
(Figure 4C), which also correlated to the CaIX-P1 binding in the
two cell lines (p,0.05) (Figure 4D).
Stability in human serum
The in vitro stability of CaIX-P1 in human serum was
investigated through incubation of the peptide at a concentration
of 10
24 mol/L in human serum and HPLC of samples taken at
different time points. The experiments revealed a degradation of
the peptide through serum proteases over time (Figure 5A). The
first degradation product of CaIX-P1 identified by HPLC was
isolated and mass spectrometry was performed in order to identify
the site of cleavage. The main product of serum degradation
appeared after 10 min incubation of the peptide in serum and had
a mass of 1270 g/mol. This mass corresponds to an 11 amino acid
Figure 1. Binding and competition of
125I-labeled CaIX-P1 on
the recombinant extracellular domain of CAIX and EGFR. Non
specific binding was determined in the presence of 10
24 M unlabeled
CaIX-P1. Mean values and standard deviation (n=3).
doi:10.1371/journal.pone.0015962.g001
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ysis of the samples revealed a half-life of CaIX-P1 of about 25 min
(Figure 5B).
In vitro kinetics of
125I-labeled CaIX-P1-2-12
Binding of the first metabolic product of CaIX-P1 in human
serum (CaIX-P1-2-12) was investigated in SKRC 52 cells. Kinetics
of
125I-CaIX-P1-2-12 in the CAIX positive cell line revealed a
time dependent increase of the radiolgand uptake for an
incubation period of 30 min. Thereafter, only a slight decrease
of the radioligand uptake was noticed for an incubation period of




performed in female Balb/c nu/nu mice, carrying subcutaneously
transplanted SKRC 52 tumors. The organ distribution revealed a
tumor uptake of 3.5% ID/g tissue at 15 min after intravenous
injection of the radioligand. Uptake in tumor was higher than in
heart, spleen, liver, muscle, intestinum and brain. Uptake in blood
(6.4%) and the kidney (7.4%) was higher. After 60 min circulation a
trend to a decrease of the uptake was noticed. This decrease was
stronger for the healthy organs than for the tumor, resulting in an
increaseofthetumor-to-organratios(Table 1).Thereafter, a further
decrease was noticed in tumor and healthy tissues (Figure 6).
Figure 2. In vitro characterization of
125I-labeled CaIX-P1. A: Binding of
125I-labeled CaIX-P1 in the CAIX positive human renal cell carcinoma
cell line SKRC 52, the human colorectal carcinoma cell line HCT 116, the CAIX negative human renal cell carcinoma cell line CaKi 2 and on human
umbilical vein endothelial cells (HUVEC). B: Displacement of bound
125I-CaIX-P1 by the unlabeled CaIX-P1 peptide at various concentrations in SKRC
52 cells. C: Specific binding of
125I-CaIX-P1 in SKRC 52 cells. Non specific binding was determined in the presence of 10
25 M unlabeled CaIX-P1.
Octreotide was used at the same concentration (10
25 M) as negative control competitor. D: In vitro cell accumulation of
125I-CaIX-P1 in SKRC 52 cells
as a function of time. Incubation was performed for time periods from 10 min to 360 min. Mean values and standard deviation (n=3).
doi:10.1371/journal.pone.0015962.g002
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peptide demonstrated an uptake decrease in the tumor, but not in
the healthy tissues, resulting in a decrease of the tumor-to-organ
ratios. In particular, after 15 min circulation a decrease of about
25% for the tumor-to-muscle ratio was noticed (p,0.05) when the
unlabeled peptide was co-injected, compared to the ratio without
blocking. 60 min after intravenous injection, the tumor-to-muscle
ratio was about 40% lower when the unlabeled peptide was co-
injected, compared to the ratio without blocking. Tumor-to-organ
ratios for all healthy tissues after blocking are presented in Table 1.
HPLC analysis of blood samples taken at 1 h post injection
revealed that the majority of the radioactivity in blood was
associated to serum proteins, while further amounts of free iodide
and small peptide fragments were detected (data not shown).
Discussion
Tumor hypoxia is known to be one of the key factors for
malignant tumor aggression and progression, representing an
independent negative prognostic factor for therapy outcome.
Various experimental and clinical studies have confirmed the
major role of hypoxia in treatment failure of both radiation
therapy and chemotherapy [23] with an up to 3-fold resistance to
radiation therapy. Oxygen deficiency leads to a reduced
production of cytotoxic reactive species and promotes via
accumulation of HIF-1a the upregulation of a variety of genes,
such as glycolysis-associated genes or the vascular endothelial
growth factor (VEGF), which not only induces angiogenesis but
also protects the endothelial cells from irradiation [24].
The leading role of tumor hypoxia for therapy outcome and
disease prognosis reveals the necessity for the development of
hypoxia targeting and imaging assays. In the past years several
tracers have been developed for hypoxia imaging using positron
emission tomography (PET) [25]. Among them fluorine-18-
labeled fluoromisonidazole (
18F-FMISO) has been extensively
evaluated in both preclinical and clinical trials demonstrating a
significantly higher retention of the tracer in hypoxic than in
normoxic tumors and a correlation between uptake and treatment
response [26,27].
A prominent intrinsic marker of tumor hypoxia is carbonic
anhydrase IX (CAIX). CAIX is a tumor-associated member of the
family of carbonic anhydrases that contributes to the acidification
of extracellular pH and neutralization of intracellular pH
protecting tumor cells from acidic pericellular microenvironment
[28]. In this study we present the results of the evaluation of CaIX-
P1, a new linear dodecapeptide with specificity for the extracel-
lular domain of human carbonic anhydrase IX, identified through
the technology of phage display. Binding experiments on the
immobilized extracellular domain of CAIX revealed a higher
accumulation on carbonic anhydrase IX, compared to the
extracellular domain of the epidermal growth factor receptor,
which was used as negative control target-protein. Tracer
accumulation was found to be inhibited by the unlabeled CaIX-
P1 peptide, which is evidence for a specific binding to the target.
The hypothesis of a specific binding is supported by the results of
the in vitro experiments, which demonstrated a higher accumula-
tion in the known CAIX-positive SKRC 52 cell line [29], while the
binding of the peptide was reduced to the background level for the
cell line CaKi 2 which has been described as CAIX negative [29].
In addition, a dependence of binding of the radiolabeled peptide
on the CAIX mRNA expression was shown for the colorectal
carcinoma cell line HCT 116 and for human umbilical vein
endothelial cells. Both mRNA expression of carbonic anhydrase
IX and binding capacity of the CaIX-P1 peptide were higher for
HCT 116 compared to the HUVEC cells. For the colorectal
carcinoma HCT 116 cells the qRT-PCR analysis revealed a cell
density dependent expression of CAIX, which also correlated to
the binding of
125I-labeled CaIX-P1. Further evidence for a
specific accumulation of the CaIX-P1 peptide was found in
competition experiments revealing that the uptake of the
radiolabeled ligand in CAIX positive SKRC 52 cells was reduced
with increasing concentration of the unlabeled peptide, whereas
Figure 3. Binding and internalization of
125I-CaIX-P1 in SKRC 52 cells. Cells were incubated with the radioligand for 10 min, 60 min, 120 min
and 240 min at 37uCo ra t4 uC. Mean values and standard deviation (n=3).
doi:10.1371/journal.pone.0015962.g003
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The results of the internalization experiments demonstrated a
quick internalization of the peptide at 37uC, which thereafter
decreased with progression of time. Experiments at 4uC revealed a
strongly reduced internalization to the background level. Those
results are in concert with the results of previous studies,
investigating CAIX specific antibodies. In particular, Chrastina et
al. demonstrated a quick internalization of
125I-labeled monoclonal
antibody M75, which is specific for human carbonic anhydrase IX,
in human colorectal carcinoma cells [16]. Furthermore, the authors
of this study point to the fact that antibodies, iodinated through the
tyrosine residues, are dehalogenated after internalization and that
the radioactive metabolites are excreted from the cells [16]. Such a
process of intracellular dehalogenation or degradation, leading to
radioactive products that are excreted by the cells, might also
explain the time dependent reduction of both internalized activity
and total cellular uptake of
125I-labeled CaIX-P1 at 37uC. The fact
that the peptide CaIX-P1-2-12 shows different kinetics with slower
decrease of the in vitro binding activity, allows the hypothesis that the
radiolabeled N-terminal tyrosine residue is mostly affected by
processesofinvitrodehalogenation ordegradation,hypothesis which
however has to be further investigated.
A prerequisite for the use of a ligand as tracer for imaging
purposes is a higher in vivo accumulation in tumor tissue, compared
to the healthy organs. Although organ distribution studies in nude
mice bearing SKRC 52 tumors revealed a higher uptake in the
tumor than in most of the healthy organs the blood values were
higher, resulting in an enhanced background, which is a drawback
for the use of the native peptide as imaging agent. With
Figure 4. Quantitative RT-PCR analysis of CAIX mRNA in HCT 116 and HUVEC cells. A: CAIX mRNA levels in HCT 116 cells as function of the
cell density. B: Binding of
125I-CaIX-P1 in HCT 116 cells as function of the cell density. C: CAIX mRNA levels in HCT 116 and HUVEC cells at the same cell
density. D: Binding of
125I-CaIX-P1 in HCT 116 and HUVEC cells at the same density. Mean values and standard deviation (n=3).
doi:10.1371/journal.pone.0015962.g004
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healthy organs and the tumor is noticed. This reduction is stronger
in the healthy tissues than in the tumor for a circulation period of
up to 60 min, resulting in an increase of the tumor-to-organ ratios.
Thereafter however, a further uptake reduction in tumor and
organs leads to a decrease of the tumor-to-organ ratios, which is
disadvantageous for in vivo applications. The fast washout from the
tumor is in concert with the results of the in vitro kinetic and
internalization experiments and might also be explained by an
intracellular dehalogenation or degradation process. Co-injection
of unlabeled peptide in in vivo blocking experiments led to a
significant reduction of the tumor-to-muscle ratios of about 25%
after 15 min, which reached the level of about 40% after 60 min.
Similar results were also revealed for other healthy organs,
indicating an in vivo specificity of CaIX-P1.
The enhanced blood values are explained through an interaction
ofthe peptide withserumproteins,suchas albuminorthrough invivo
deiodination of the radioligand. HPLC analysis of blood at 1 h after
injection of
131I-labeled CaIX-P1 revealed that the majority of the
radioactivity was associated to serum proteins. In addition, free
iodide and small peptide fragments were detected. In vivo
deiodination of directly radiolabeled peptides has been described
in the literature [30]. This problem can be adressed through
chemical modifications of the peptide. A possible way to enhance
resistance to deiodination of peptides is the protection of the
radioiodinated N-terminal tyrosine with a t-butyloxycarbonyl group
Figure 5. Serum stability analysis of CaIX-P1. A: HPLCanalysis ofaliquots collectedat timepointsfrom0 min to120 min. Therightpeak represents
the peptide CaIX-P1 and the left peak represents the first product of the peptide degradation in serum. B: Serum stability in human serum at 37uC.
doi:10.1371/journal.pone.0015962.g005
Table 1. Tumor-to-organ ratios.
Tumor to organ Ratio 15 min 60 min 240 min 15 min blocking 60 min blocking
Blood 0.54160.064 0.65260.244 0.56560.119 0.41960.046 0.49760.078
Heart 1.66460.191 2.50661.980 1.55160.282 1.28960.232 1.42360.330
Lung 0.74460.096 1.23261.245 0.81860.207 0.58760.079 0.67460.178
Spleen 1.25860.142 1.58561.122 1.09560.240 1.00760.143 1.15260.117
Liver 1.24860.138 1.81361.095 1.23960.223 0.90760.121 1.22660.232
Kidney 0.47460.088 0.79760.510 0.61160.144 0.33360.079 0.50160.078
Muscle 2.52960.310 4.11162.444 2.78160.599 1.88460.463 2.62360.264
Intestinum 1.29960.301 1.39660.546 0.85960.492 1.14560.069 0.86460.226
Brain 7.73661.066 17.6069.740 17.1965.018 6.63161.725 9.7164.034
Tumor-to-organ ratios were calculated from the organ distribution of
131I-CaIX-P1 in female Balb/c nu/nu mice carrying SKRC 52 tumors after 15 min (n=8 animals),
60 min (n=10 animals) and 240 min (n=3 animals) circulation of the radioligand in the blood stream. For in vivo blocking, 100 mL unlabeled peptide at a concentration
of 10
23 M was co-injected with the radioligand and tumor-to-organ ratios were calculated after 15 min (n=3 animals) and 60 min (n=3 animals) circulation in the
blood stream.
doi:10.1371/journal.pone.0015962.t001
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labeling through a chelator might be applied in order to improve
labeling stability and reduce radioactive background [32]. In case of
CaIX-P1 the high blood value is additionally explained by the
metabolic properties of the peptide. Stability experiments in human
serum demonstrated a degradation of CaIX-P1 through serum
proteases. Mass spectrometry revealed a degradation of a tyrosine
molecule. Since direct iodination is performed on the side group of
tyrosine, the degradation might lead to free
125I-labeled tyrosine
residues that circulate in the bloodstream. In this way the organ
distribution of CaIX-P1 is negatively influenced by both radiolabel-
ing and metabolic instability. Therefore, a major issue of further
investigation is the serum stabilization of the CaIX-P1 peptide.
Methods to achieve improved serum stability are synthesis of shorter
derivatives of the peptide, exchange of amino acids by unnatural
amino acids that can not be recognized by serum proteases,
acetylation or pegylation of the molecule [33,34] and grafting of the
bindingmotifintoastablescaffoldstructure[35].Suchmodifications
might improve the metabolic properties of the peptide, increase its
affinity and binding capacity on the target structure and lead to
enhanced tumor-to-organ ratios, which is of high importance for the
development of in vivo targeting and imaging strategies.
In conclusion, peptides with affinity for the tumor associated
carbonic anhydrase IX can be used as lead structures for targeting
of imaging agents in hypoxic tumor sites. The evaluation of the
newly identified peptide CaIX-P1 indicates that the peptide might
be a promising candidate, which could be used as lead structure
for the development of new tracers with affinity for human
carbonic anhydrase IX. Based on the results of the in vitro
experiments the hypothesis of a specific binding to the target can
be generated. However, the organ distribution studies demonstrate
low tumor-to-blood ratios, which is disadvantageous for the
clinical use of the native ligand for imaging purposes. Therefore,
further studies are needed in order to improve the serum stability
of CaIX-P1, optimize its binding efficacy and lead to generation of
peptide-based ligands, which can be used for targeting human
carbonic anhydrase IX and tumor hypoxia.
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